Concepedia

John Panagides

JP

Statistics

Publications

33

Citations

1.8K

H-Index

23

Active since

1976

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

MSD (Netherlands)

University of Toronto

Harvard University

John Panagides is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in psychopharmacology, pharmacology, and psychiatry.

ORCID

Publications per year

1976–2023

33

Publications

33

A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

Roger S. McIntyre, Miriam Cohen, Jun Zhao et al. · Bipolar Disorders · 2009 · 188 citations

, , +17

Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial

Roger S. McIntyre, Miriam Cohen, Jun Zhao et al. · Journal of Affective Disorders · 2010 · 160 citations

, , +9

Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia

John M. Kane, Michael N. Cohen, Jun Zhao et al. · Journal of Clinical Psychopharmacology · 2010 · 127 citations

, , +17

Asenapine versus olanzapine in acute mania: a double‐blind extension study

Roger S. McIntyre, Miriam Cohen, Jun Zhao et al. · Bipolar Disorders · 2009 · 113 citations · Full text

, , +16

Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder.

Ward T. Smith, Vincent Glaudin, John Panagides et al. · PubMed · 1990 · 111 citations

, , +17

1–5 of 33